Focal therapy using a novel cooled laser device for prostate cancer: early trial results
Authors:
Open Access
- 28 January 2026
- journal article
- Published by Wiley in BJU International
- Vol. 138 (S2) , S74-S80
Abstract
Objectives: To determine the short‐term oncological results and safety of the ProFocal Laser Therapy for Prostate Tissue Ablation (PFLT‐PC) trial, the first phase II clinical trial of ProFocal® (Medlogical Innovations, Sydney, Australia), a novel, cooled laser focal therapy (cLFT) device for prostate cancer (PCa) treatment. Patients and Methods: Men with localised PCa, prostate‐specific antigen (PSA) level ≤15 ng/mL, T stage ≤T2c, International Society of Urological Pathology (ISUP) score 2–3 concordant with multiparametric magnetic resonance imaging (mpMRI) visible disease were recruited for this trial (Australian and New Zealand Clinical Trial Registry [ACTRN]12618001774213p) at Nepean Hospital, Australia. The cLFT was performed under general anaesthesia as a day procedure. Primary outcome was adequacy of tissue ablation assessed by mpMRI within 72 h and biopsy at 3 months. Secondary outcomes of functional measures were assessed using validated questionnaires (International Prostate Symptom Score, Sexual Health Inventory for Men [SHIM], Expanded Prostate cancer Index Composite [EPIC], 12‐item Short‐Form Health Survey). Complications and adverse events within 90 days were reported using Clavien–Dindo classification grading. Results: A total of 100 patients were recruited. The median (interquartile range [IQR]) age was 66 (60–72) years, PSA level 5.9 (3.9–7.6) ng/mL, prostate volume 39 (30–51) mL and MRI lesion volume 0.84 (0.57–1.2) mL. The median (IQR) treatment time was 60 (47–70) min. In all, 84% had no ISUP Grade Group ≥2 PCa in their 3‐month treatment zone biopsies. Erectile dysfunction was reported in 12% of the men, with a 15% mean decline in the SHIM and EPIC‐sexual domains scores. There was a 4.5% decrease on EPIC‐urinary domain scores. There was no decline in any other functional measures. This study's main limitations were the absence of a control group and the short follow‐up. Conclusions: The PFLT‐PC trial demonstrates that at 3 months, cLFT using the ProFocal device provides an 84% treatment success with low morbidity.Keywords
This publication has 18 references indexed in Scilit:
- A clinical evaluation of robotic-assisted radical prostatectomy (RARP) in located prostate cancer: A systematic review and network meta-analysisCritical Reviews in Oncology/Hematology, 2024
- Systematic review on urinary continence rates after robot-assisted laparoscopic radical prostatectomyIrish Journal of Medical Science (1971 -), 2024
- Decision Regret in Patients with Localised Prostate Cancer: A Systematic Review and Meta-analysisEuropean Urology Oncology, 2023
- An Updated Systematic Review on Focal Therapy in Localized Prostate Cancer: What Has Changed over the Past 5 Years?European Urology, 2022
- EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer—2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative IntentEuropean Urology, 2021
- Focal ablation of apical prostate cancer lesions with irreversible electroporation (IRE)World Journal of Urology, 2020
- Focal Laser Ablation of Prostate Cancer: Results in 120 Patients with Low- to Intermediate-Risk DiseaseJournal of Vascular and Interventional Radiology, 2019
- Annual Report to the Nation on the Status of Cancer, part II: Recent changes in prostate cancer trends and disease characteristicsCancer, 2018
- Urinary Incontinence and Erectile Dysfunction After Robotic Versus Open Radical Prostatectomy: A Prospective, Controlled, Nonrandomised TrialEuropean Urology, 2015
- Minimally Important Difference for the Expanded Prostate Cancer Index Composite Short FormUrology, 2015